

Appl. No. 10/748,887  
Amdt. Dated March 13, 2007  
Reply to Office Action of September 15, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1 (currently amended): A method for lowering sex hormone levels in a human subject in need of treatment, comprising administering to the subject an effective amount of an LHRH-antagonist, wherein said LHRH-antagonist is peptidic ~~or non-peptidic~~, the lowered sex hormone levels in said subject result in modification of the T-cell population in said subject, and said LHRH-antagonist will lower sex hormone levels but not to the point of castration or below the castration level of said subject.

Claim 2 (previously amended): A method for lowering sex hormone levels in a human subject in need of treatment, comprising administering to the subject an effective amount of an LHRH-antagonist to said subject wherein the lowered sex hormone levels in said subject result in modification of the T-cell population in said subject.

Claim 3 (canceled).

Claim 4 (previously amended): A method for lowering sex hormone levels in a human subject in need of treatment, comprising administering to the subject an effective amount of an LHRH-antagonist to said subject wherein the lowered sex hormone levels in said subject result in a modification of the T-cell population in an individual suffering from a

Appl. No. 10/748,887  
Amdt. Dated March 13, 2007  
Reply to Office Action of September 15, 2005

HIV infection, cancer, an auto-immune disease, endometriosis, asthma, arthritis, dermatitis, multiple sclerosis, Jacob Creutzfeldt-disease, or Alzheimer's disease.

Claim 5 (canceled).

Claim 6 (canceled).

Claim 7-11 (withdrawn).

Claim 12 (Currently amended): The method according to any one of claims 1-6, wherein said LHRH-antagonist is chosen from CETRORELIX, TEVERELIX, ~~ANTIDE~~, ITURELIX or ABARELIX.

Claim 13 (previously amended): The method according to any one of claims 1-6, wherein said LHRH-antagonists is CETRORELIX or a pharmaceutically acceptable salt form thereof.

Claim 14 (currently amended): The method according to any one of claims 1-6, wherein said effective amount of an LHRH-antagonist is administered at a dose of about 5 mg to 120 mg for a period ranging from 1 to 8 weeks and optionally repeating said method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject hormones.

Claim 15 (currently amended): The method according to any one of claims 1-6, wherein the LHRH-antagonist CETRORELIX PAMOATE is administered at a dose of about 30 mg to 120 mg for a period ranging from 1 to 4 weeks and optionally repeating said

Appl. No. 10/748,887  
Amdt. Dated March 13, 2007  
Reply to Office Action of September 15, 2005

method of lowering sex ~~hormone levels every 3 to 4 months while there is still a need of~~  
~~treatment by said subject~~ hormones.

Claim 16 (currently amended): The method according to any one of claims 1-6, wherein  
the LHRH-antagonist CETRORELIX ACETATE is administered in a dose of about 5 mg  
to 80 mg for a period ranging from 1 to 8 weeks and optionally repeating said method of  
lowering sex ~~hormone levels every 3 to 4 months while there is still a need of treatment~~  
~~by said subject~~ hormones.